Gut microbiota shaping fatty liver disease progression
- 1Laboratory of Cellular Genomics, International Institute of Molecular and Cell Biology
Abstract
The gut–liver axis is an important regulator of homeostasis, and its dysregulation has been implicated in the pathogenesis of metabolic dysfunction–associated steatotic liver disease (MASLD). In this review, we summarize current knowledge on both compositional alterations of the gut microbiome in MASLD and the functional consequences of these changes. We first discuss changes across major microbial domains, including bacteria, archaea, eukaryota, and bacteriophages, and then focus on microbiota-derived metabolites, such as short-chain fatty acids, trimethylamine and its derivative trimethylamine N-oxide, tryptophan-derived indoles, secondary bile acids, and other bioactive compounds. Their complex impacts on intestinal barrier integrity, inflammation, lipid and glucose metabolism, and immune and hormonal signaling in the liver are highlighted. We further examine mechanisms involving the translocation of microbial products and the modulation of nuclear and membrane receptors. Finally, we outline current challenges and knowledge gaps that need to be addressed to better understand the role of the gut microbiota in MASLD.
Related
- A nested case-control study on the relationship between gut microbiota and non-alcoholic fatty liver disease
- Fucoidan attenuates metabolic dysfunction-associated fatty liver disease in mice and is associated with gut microbiota remodeling and AMPK/PPARγ signaling
- Integrating host-microbiota metabolic networks: how aromatic amino acids shape immune homeostasis and affect disease progression
- The ability of FGF21 to ameliorate signs of non-alcoholic fatty liver disease in mice depends on sex and diet.
- Small-Intestinal Motility Interrelates With Fecal Microbiota, Metabolites and Metabolic Tissue Gene Expression in Metabolic Dysfunction-Associated Steatotic Liver Disease
BibTeX
@article{wysokinska2026microbiota,
title = {{Gut microbiota shaping fatty liver disease progression}},
author = {Martyna Wysokińska and Marta Mysza and Aleksandra E Uryga and Aleksandra A Kołodziejczyk},
journal = {Life Science Alliance},
year = {2026},
month = oct,
doi = {10.26508/lsa.202603756},
url = {https://www.life-science-alliance.org/lookup/doi/10.26508/lsa.202603756},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiota shaping fatty liver disease progression
AU - Martyna Wysokińska
AU - Marta Mysza
AU - Aleksandra E Uryga
AU - Aleksandra A Kołodziejczyk
PY - 2026
DA - 2026/10/12
JO - Life Science Alliance
DO - 10.26508/lsa.202603756
UR - https://www.life-science-alliance.org/lookup/doi/10.26508/lsa.202603756
AB - The gut–liver axis is an important regulator of homeostasis, and its dysregulation has been implicated in the pathogenesis of metabolic dysfunction–associated steatotic liver disease (MASLD). In this review, we summarize current knowledge on both compositional alterations of the gut microbiome in MASLD and the functional consequences of these changes. We first discuss changes across major microbial domains, including bacteria, archaea, eukaryota, and bacteriophages, and then focus on microbiota-derived metabolites, such as short-chain fatty acids, trimethylamine and its derivative trimethylamine N-oxide, tryptophan-derived indoles, secondary bile acids, and other bioactive compounds. Their complex impacts on intestinal barrier integrity, inflammation, lipid and glucose metabolism, and immune and hormonal signaling in the liver are highlighted. We further examine mechanisms involving the translocation of microbial products and the modulation of nuclear and membrane receptors. Finally, we outline current challenges and knowledge gaps that need to be addressed to better understand the role of the gut microbiota in MASLD.
SN - 2575-1077
ER -